COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
1 . A method for treating a mammalian subject with a condition selected from the group consisting of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis comprising administering to the subject an amount of a biologically active agent effective to treat the condition, wherein the agent is a compound of the formula:
wherein
n is 1 or 2;
R 1 is hydrogen or alkyl having from 1 to 3 carbon atoms; and
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or
cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or
a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula XCI by a ring carbon;
or a pharmaceutically acceptable salt of the compound.
2 . The method of claim 1 , wherein the agent is administered orally.
3 . The method of claim 1 , wherein the subject is a human.
4 . The method of claim 3 , wherein the agent is administered in an amount from one milligram to four hundred milligrams per day.
5 . The method of claim 1 , wherein the condition is insulin resistance syndrome or Type II Diabetes.
6 . The method of claim 1 , wherein the condition is Type 1 Diabetes.
7 . The method of claim 1 , wherein the treatment reduces a symptom of diabetes or the chances of developing a symptom of diabetes, wherein the symptom is selected from the group consisting of: atherosclerosis, obesity, hypertension, hyperlipidemia, fatty liver disease, nephropathy, neuropathy, retinopathy, foot ulceration and cataracts, associated with diabetes.
8 . The method of claim 1 , wherein the compound is 4-(3-(2,6-Dimethylbenzyloxy)phenyl)-3-butenoic acid.